Precision Business Insights

Portfolio

Research Reports

SELECT LICENSE TYPE
Databank $ 2,000.00
spinner
Single User $ 3,000.00
spinner
Multiple User $ 4,000.00
spinner
Corporate User $ 6,000.00
spinner
buy now spinner

Why Precision Business Insights?

  • Pre and Post Sale Support

    Get in touch with our industry experts to resolve your research queries before and after buying the report. Avail free 60 minutes analyst tele-call to get additional market information before and after purchase

  • Special Pricing and Discounts

    Avail special pricing for the purchase of report sections,regional insights, and historical data. Discounts for government bodies, research institutes, universities, NGO’s and start-up’s

  • In-depth Market Analysis

    Our research reports provides holistic market information with 360 degree analysis. We adopt 3 pronged strategy to analyze the market i.e. Secondary research , primary research, and expert validation

  • Accurate and Reliable Market Data

    Utmost focus on delivering accurate and reliable research reports. We adopt internally developed data mining tools to eliminate any data errors

  • NICHE AND GROWTH MARKETS EXPERTISE

    Proven expertise in delivering new and emerging markets product and technology advancements. We provide market information across the developed and emerging markets

  • ADHERING TO QUICK DELIVERY TIME LINES

    We provide impeccable research reports in quick turnaround time

Onychomycosis Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018


 

Available formats:    

StumbleUponEmail

Onychomycosis Pipeline Drugs

 

Onychomycosis Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

 

Overview:

Onychomycosis is a fungal infection of fingernails or toenails, known as tinea unguium. Onychomycosis is common and occurs in about 10% of adult population. Nail changes may include, change in shape, brittleness, discoloration, debris trapped under the nail, detachment and thickening of the nail. Physicians can identify fungal nail infection by performing an examination most oftime. A sample may be taken from the debris beneath the nail and examined microscopically or cultured for possible fungal growth. Oral medications are generally required and sometimes they are combined with nail removal and/or application of nail lacquer. Presently available oral antifungal medications include: terbinafine, itraconazole, and fluconazole taken daily, in pulse or weekly, respectively.

 

Segmentation:

By route of administration, onychomycosis pipeline drugs are segmented into

  • Oral
  • Topical
  • Parenteral
  • Others

By Trial Phase, Onychomycosis pipeline drugs are segmented as:

  • Preclinical Trials
  • Phase 1
  • Phase 2
  • Phase 3

By company, Onychomycosis pipeline drugs are segmented into

  • Polichem S.A. (Switzerland)
  • Hisamitsu Pharmaceutical Co., Inc. (Japan)
  • Viamet Pharmaceuticals, Inc. (U.S.)
  • Galderma S.A.
  • Others

 

Space Analysis:

  • In April 2017, Novan, Inc. announced positive top line results from the Company’s Phase-II clinical trial with SB208, as a broad-spectrum anti fungal gel for the treatment of superficial cutaneous fungal infections of the skin and nails, including tinea pedis and onychomycosis.
  • In January 2017, Viamet Pharmaceuticals, Inc. announced positive results from RENOVATE, its Phase 2b clinical trial of VT-1161 in onychomycosis of the large toenail.

 

Report Description:

Onychomycosis Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Onychomycosis treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Onychomycosis disease pipeline drugs development. This report studies the dynamics of the Onychomycosis Disease Pipeline Drugs i.e. drivers, challenges, and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Onychomycosis disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

 

Key Features of the Report:

  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis of each drug candidates in the clinical trial phases
  • Polichem S.A. (Switzerland)
  • Hisamitsu Pharmaceutical Co., Inc. (Japan)
  • Viamet Pharmaceuticals, Inc. (U.S.)
  • Galderma S.A.
  • Others

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

 

Avail Discount  Up To 20%

Need more discount on this report?

Call or e-mail us for:

(U.S.) – +1-866-598-1553

Contact SalesTOLL FREE: +1-866-598-1553